索拉非尼联合TACE治疗老年原发性肝癌的临床观察

Clinical observation of sorafenib combined with transcatheter arterial chemoembolization for treating senile primary carcinoma of the liver

目的探讨老年原发性肝癌患者采用索拉非尼联合经导管肝动脉化疗栓塞(TACE)治疗的临床观察。方法选择56例老年原发性肝癌患者,随机分索拉非尼联合TACE治疗组(观察组)28例,单纯TACE治疗组(对照组)28例;按照RECIST标准评价客观有效率(ORR)、临床获益率(CBR)、6个月生存率、1年生存率、2年生存率,甲胎蛋白(AFP)的变化及不良反应。结果治疗组ORR、CBR、6个月生存率、1年生存率和2年生存率分别为57.1%、96.4%、100%、80.9%和75.0%,对照组分别为25.0%、67.9%、78.6%、60.7%和42.9%,差异有显著性(P<0.05)。结论索拉非尼联合TACE治疗老年肝癌疗效较好,毒副反应能耐受。

【Objective】 To observe the treatment of sorafenib combined with transcatheter arterial chemoembolization（TACE） for senile primary carcinoma of the liver.【Methods】 56 cases of patients were selected according to the randomized method and divided into treatment group（sorafenib combined with TACE group） and control group（TACE group） randomly,28 cases each;Standard RECIST was used to evaluate objective response rate（ORR）,clinical benefit response（CBR）,half year survival rate,1 year survival rate,2-year survival rate and observing the change of alpha fetoprotein（AFP） and toxicity.【Result】 Treatment group ORR,CBR,half year survival rate,1 year survival rate,2-year survival rate were 57.1%,96.4%,100%,80.9%,75.0% respectively,higher than that in the control group 25.0%,67.9%,78.6%,60.7%,42.9%,and there was significant difference（P 0.05）.【Conclusions】 Sorafenib combined with TACE for elderly patients with primary liver cancer has better treatment efficacy,and the toxic reaction can be tolerated.